Literature DB >> 22341674

Bile duct hepatocellular carcinoma thrombi.

Hugo Uchima-Koecklin1, Domingo Balderramo, Andrés Cárdenas.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third cause of death related to cancer. Through the application of surveillance programs the percentage of early diagnosis has increased but the diagnosis is still made at advanced stages in some patients. The presentation of HCC as progressive jaundice secondary to bile duct tumor thrombi is uncommon. In such cases it is extremely difficult to distinguish such biliary lesions from cholangiocarcinoma or even common bile stones. We report a case of a 34-year-old male patient with common bile duct invasion secondary to HCC that mimicked choledocholithiasis. The diagnosis of HCC was confirmed after thrombi extraction during ERCP.
Copyright © 2011 Elsevier España, S.L. and AEEH y AEG. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22341674     DOI: 10.1016/j.gastrohep.2011.12.004

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  3 in total

1.  Radiofrequency Ablation of the Main Lesion of Hepatocellular Carcinoma and Bile Duct Tumor Thrombus as a Radical Therapeutic Alternative: Two Case Reports.

Authors:  Jun Gao; Qingshuai Zhang; Jun Zhang; Jian Kong; Shaohong Wang; Xuemei Ding; Shan Ke; Wenbing Sun
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

2.  Prognosis of hepatocellular carcinoma patients with bile duct tumor thrombus after hepatic resection or liver transplantation in Asian populations: A meta-analysis.

Authors:  Chenglin Wang; Yu Yang; Donglin Sun; Yong Jiang
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

3.  Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis.

Authors:  Xinwei Yang; Zhiquan Qiu; Rongzhen Ran; Longjiu Cui; Xiangji Luo; Mengchao Wu; Wei-Feng Tan; Xiaoqing Jiang
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.